CANHERA 440 mg Powder and Solvent for Solution for Injection is a specialized medication designed for the targeted treatment of certain types of cancer. This product, containing the active ingredient Trastuzumab, is a biosimilar to Herceptin and is crucial in oncology for patients with HER2-positive cancers. It comes as a lyophilized powder in a vial, which needs to be reconstituted with the provided solvent before intravenous administration. As referenced by leading pharmaceutical platforms such as Nahdi Online, , and , CANHERA is a key therapy in the management of HER2-positive malignancies.

• Targeted Cancer Therapy: CANHERA (Trastuzumab) specifically targets the HER2 protein found on the surface of some cancer cells, thereby inhibiting their growth and proliferation with reduced impact on healthy cells.
• Effective in HER2-Positive Cancers: It is highly effective in the treatment of HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma.
• Improved Patient Outcomes: When used as part of a comprehensive treatment regimen, CANHERA can lead to improved progression-free survival and overall survival rates for eligible patients.
• Biosimilar Option: Provides an accessible and equally effective treatment alternative to the reference product.

CANHERA 440 mg Powder and Solvent for Solution for Injection must be administered by a qualified healthcare professional. It is given as an intravenous infusion.

1. Reconstitution: The lyophilized powder must first be reconstituted with the provided sterile water for injection.
2. Dilution: The reconstituted solution is then further diluted into an infusion bag containing 0.9% sodium chloride solution.
3. Administration: Administer intravenously over a specified period, typically 30 to 90 minutes, depending on the dose and patient tolerance.
4. Dosage Schedule: The dosage and frequency of administration are determined by the treating physician based on the patient's body weight, cancer type, and stage.
5. Monitoring: Patients will be closely monitored during and after infusion for any adverse reactions.

• Cardiac Dysfunction: Patients should be monitored for signs and symptoms of cardiac dysfunction, including congestive heart failure. Pre-existing cardiac conditions should be carefully evaluated.
• Infusion-Related Reactions: Severe infusion-related reactions, including anaphylaxis, can occur. Patients should be observed during and for at least 6 hours after the first infusion and 2 hours after subsequent infusions.
• Pulmonary Toxicity: Cases of severe pulmonary events, including interstitial pneumonitis, lung fibrosis, and acute respiratory distress syndrome, have been reported.
• Embryo-Fetal Toxicity: CANHERA can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should use effective contraception during treatment and for 7 months following the last dose.
• Not for Intravenous Push or Bolus: CANHERA should only be administered as an intravenous infusion. Do not administer as an intravenous push or bolus.
• Storage: Store the unreconstituted vial in a refrigerator (2°C - 8°C) and protect from light. Do not freeze.

• Active Ingredient: Trastuzumab 440 mg
• Excipients: The powder typically contains L-histidine, L-histidine hydrochloride monohydrate, alpha,alpha-trehalose dihydrate, and polysorbate 20. The solvent is sterile water for injection.

• Strength: 440 mg
• Form: Lyophilized powder for solution for injection
• Packaging: Single-use vial with solvent
• Administration Route: Intravenous (IV) infusion
• Manufacturer: Richter Gedeon Plc.
• Storage: Refrigerated (2°C - 8°C)